Entries RSS

 

Site update

Due to some unforeseen technical problems updating of this site will be intermittent for the next two weeks. Normal service should resume thereafter. We apologize for the inconvenience

BMS publish discovery of Met inhibitor BMS-777607

Researchers publish series of Sterile 20 kinase inhibitors

Teva submit ANDA for Tarceva

OSI has announced that  it has received a Paragraph IV Certification Notice Letter advising that Teva has submitted an Abbreviated New Drug Application (ANDA) to the U.S. FDA requesting permission to manufacture and market a generic version of Tarceva (erlotinib).

Aveo’s present Phase II data on VEGFR inhibitor AV-951

AVEO Pharmaceuticals are to present interim safety and efficacy results from a Phase II clinical trial of AV-951 at the 2009 Genitourinary (GU) Cancers Symposium.